text
"['\nIX. 계열회사 등에 관한 사항\n가. 계열회사 출자 현황\n(기준일: 2019년 12월 31일)\n(단위 : %)\n계열회사명\n사업자등록번호\n투\xa0 자\xa0 자\n서 정 진\n(주)셀트리온\n(주)셀트리온홀딩스\n(주)셀트리온헬스케어\n(주)셀트리온스킨큐어\n(주)셀트리온제약\nCelltrion Group Hongkong\nVcell Healthcare\n계\n(주)셀트리온\n133-81-23603\n-\n-\n20.05\r\n-\n2.12\n-\n-\n-\n22.17\n(주)셀트리온홀딩스\n131-86-24858\n95.51\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n95.51\n(주)셀트리온헬스케어\n123-81-53473\n35.68\n\xa0-\n\xa0-\n\xa0-\n1.39\n\xa0-\n\xa0-\n\xa0-\n37.07\n(주)셀트리온스킨큐어\n105-86-13560\n69.66\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n69.66\n셀트리온 유럽\n-\n\xa0-\n\xa0 \xa0 \xa0\xa0 100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n100.00\n셀트리온 예브라지아\xa0\n-\n\xa0-\n\xa0 \xa0 \xa0\xa0 100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n100.00\nCelltrion Group Hongkong\n-\n\xa0-\n\xa0 \xa0 \xa0\xa0 70.00\n\xa0-\n30.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n100.00\nVcell Healthcare\n-\n\xa0-\n-\n-\n-\n-\n-\n100.00\n-\n100.00\nShanghai Vcell Biotech\n-\n\xa0-\n-\n-\n-\n-\n-\n-\n100.00\n100.00\n(주)셀트리온제약\n214-86-71641\n\xa0-\n54.99\n-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n54.99\n(주)셀트리온엔터테인먼트\n107-87-63802\n\xa0-\n\xa0-\n100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n100.00\nCelltrion Pharma USA\n-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0 \xa0 \xa0\xa0 100.00\n\xa0 \xa0 \xa0\xa0 -\n\xa0 \xa0 \xa0\xa0 -\n100.00\nCelltrion Global Safety Data Center\n-\n-\n99.99\n-\n-\n-\n-\n-\n-\n99.99\nCelltrion USA, Inc.\n-\n-\n100.00\n-\n-\n-\n-\n-\n-\n100.00\n㈜셀트리온 충북대 바이오메딕스\n417-87-01299\n-\n50.00\n-\n-\n-\n-\n-\n-\n50.00\n㈜셀트리온 충북대 코스메틱스\n338-88-01033\n-\n-\n-\n-\n50.00\n-\n-\n-\n50.00\n나. 타법인출자 현황\xa0\n(기준일 :\xa0\n2019년 12월 31일\n)\n(단위 : 천원, 주, %)\n법인명\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nA&G Pharmaceutical, Inc.\n2006.07.14\n신약개발투자\n2,676,548\n987,889\n16.51\n116,348\n-\n-\n-9,059\n987,889\n16.51\n107,289\n2,277,282\n31,320\n셀트리온 유럽\n2009.07.21\n유럽임상관련투자\n2\n1\n100.00\n2\n-\n-\n-\n1\n100.00\n2\n2\n-\n바이오톡스텍\n2009.07.28\n투자수익\n2,025,000\n1,631,134\n11.20\n13,554,724\n-\n-\n-3,311,203\n1,631,134\n11.20\n10,243,521\n57,912,152\n3,601,874\n보스톤 인큐베이션투자조합\n2009.11.27\n투자수익\n2,500,000\n10\n25.00\n143,111\n-\n-\n-60,104\n10\n25.00\n83,007\n338,536\n-257,982\n셀트리온 예브라지아\n2009.12.09\n사업다각화\n392\n-\n100.00\n393\n-\n-\n-\n-\n100.00\n393\n393\n-\n셀트리온 돈\n2009.12.09\n사업다각화\n500,000\n100,000\n0.09\n62,994\n-\n-\n-18,098\n100,000\n0.09\n44,896\n179,780,067\n13,296,339\n제이티비씨\n2017.09.20\n투자수익\n250,000\n2,152\n6.67\n1,996,007\n1,330\n1,330,000\n7,328\n3,482\n6.67\n3,333,335\n30,318,519\n-1,531,910\n프리미어 글로벌이노베이션 1호\n2017.06.15\n유망 바이오 벤처기업투자\n1,000,000\n250,981\n0.45\n1,475,167\n-\n-\n-\n250,981\n0.45\n1,475,167\n435,586,215\n-781,407\n매일방송\n2011.03.17\n투자수익\n500,000\n60,000\n5.00\n202,251\n-\n-\n-\n60,000\n5.00\n202,251\n17,322,150\n3,576,328\n뉴스1\n2011.06.09\n투자수익\n50,057,259\n18,744,943\n55.03\n255,342,176\n-\n-\n-\n18,744,943\n55.03\n255,342,176\n470,980,396\n9,526,146\n셀트리온제약\n2013.04.23\n경영참가 등\n2,000,000\n3,993\n20.00\n3,177,244\n-200\n-200,000\n-\n3,793\n20.00\n2,977,244\n16,643,722\n1,726,446\n2014 성장사다리-IMM벤처펀드\n2014.08.11\n투자수익\n500,000\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n미래에셋셀트리온신성장투자조합 1호\n2017.03.31\n유망 바이오 벤처기업투자\n6,250,000\n250\n50.00\n25,000,000\n188\n18,750,000\n-\n438\n50.00\n43,750,000\n88,806,475\n2,138,294\nCelltrion Global Safety Data Center\n2018.05.23\n글로벌 의약품 안전성 데이터 관리\n1,106,930\n580,564\n99.99\n1,204,581\n-\n-\n-\n580,564\n99.99\n1,204,581\n1,903,425\n54,372\nCelltrion USA, Inc.\n2018.07.24\n케미컬의약품판매유통망 구축\n38,973\n1,000\n100.00\n1,244,660\n-\n1,087,870\n-\n1,000\n100\n2,332,530\n13,330,947\n1,125\nCelltrion Group Hongkong ltd\n2019.04.01\n바이오의약품 중국사업\r\n-\n-\n-\n-\n7,000,000\n8,059,100\n-\n-\n70.00\n8,059,100\n22,089,849\n-2,599,074\n셀트리온충북대바이오메딕스\n2018.07.18\n신약 및 원료의약품 연구개발\n100,000\n20,000\n50.00\n100,000\n-\n-\n-\n20,000\n50.00\n100,000\n169,969\n-19,577.00\n합 계\n22,382,917\n-\n303,619,658\n7,001,318\n29,026,970\n-3,391,136\n22,384,235\n-\n329,255,492\n1,337,460,099\n28,762,294\n']"
